文献速递心律失常冠心病

房颤患者TAVR同期行左心耳封堵的非劣效性随机试验

Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation.
PubMed 文献 · Circulation · 2023-10-24

WATCH-TAVR 多中心随机试验纳入 349 例接受 TAVR 的房颤患者,1:1 随机至 TAVR+WATCHMAN 左心耳封堵或 TAVR+药物治疗。2 年时主要复合终点(全因死亡、卒中、大出血)事件率 22.7 vs 27.3/100 患者年,HR 0.86(95%CI 0.60-1.22),非劣效性 P<0.001。同期封堵增加手术时间 38 分钟和对比剂用量。

要点

  • TAVR 合并房颤患者同期 WATCHMAN 封堵在 2 年死亡、卒中、大出血复合终点非劣于药物治疗。
  • 联合手术增加 38 分钟手术时间和对比剂用量(中位 119 mL vs 70 mL)。
  • 术后 24 个月联合组抗凝使用率 13.9%,远低于药物治疗组 66.7%。

核心结论

  • 在重度主动脉瓣狭窄合并房颤患者中,TAVR 同期 WATCHMAN 左心耳封堵在 2 年全因死亡、卒中和主要出血复合终点非劣于 TAVR 加药物治疗。
  • 联合手术复杂度增加,当将其视为药物治疗替代方案时需权衡额外风险。

研究设计与样本

  • 患者 1:1 随机至 TAVR+左心耳封堵(177 例)或 TAVR+药物治疗(172 例)。
  • WATCHMAN 组术后抗凝 45 天,随后双联抗血小板至 6 个月;药物治疗组抗凝由治疗医生决定。
  • 主要非劣效终点为 2 年全因死亡、卒中和主要出血的复合终点。

主要发现

  • 患者平均年龄 81 岁,平均 CHA2DS2-VASc 评分 4.9,HAS-BLED 评分 3.0。
  • 基线时 85.4% 患者服用抗凝药,71.3% 服用抗血小板药。
  • 联合封堵额外手术时间 38 分钟,联合手术中位对比剂用量 119 mL,单纯 TAVR 为 70 mL。
  • 24 个月时联合组与药物组任何抗血小板治疗比例分别为 82.5% 与 50.8%,任何抗凝治疗比例分别为 13.9% 与 66.7%。
  • 主要复合终点事件率联合组 22.7/100 患者年,药物组 27.3/100 患者年,HR 0.86(95%CI 0.60-1.22),非劣效性 P<0.001。

临床怎么用

  • 对于接受 TAVR 的房颤患者,可考虑同期 WATCHMAN 左心耳封堵作为药物治疗的替代策略,但需认识到手术复杂度和对比剂用量增加。
  • 联合组术后抗凝使用率显著降低,但需按方案完成 45 天抗凝及后续双联抗血小板治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) and is associated with increased risk of bleeding and stroke. While left atrial appendage occlusion (LAAO) is approved as an alternative to anticoagulants for stroke prevention in patients with AF, placement of these devices in patients with severe aortic stenosis, or when performed at the same time as TAVR, has not been extensively studied. METHODS: WATCH-TAVR (WATCHMAN for Patients with AF Undergoing TAVR) was a multicenter, randomized trial evaluating the safety and effectiveness of concomitant TAVR and LAAO with WATCHMAN in AF patients. Patients were randomized 1:1 to TAVR + LAAO or TAVR + medical therapy. WATCHMAN patients received anticoagulation for 45 days followed by dual antiplatelet therapy until 6 months. Anticoagulation was per treating physician preference for patients randomized to TAVR + medical therapy. The primary noninferiority end point was all-cause mortality, stroke, and major bleeding at 2 years between the 2 strategies. RESULTS: The study enrolled 349 patients (177 TAVR + LAAO and 172 TAVR + medical therapy) between December 2017 and November 2020 at 34 US centers. The mean age of patients was 81 years, and the mean scores for CHA2DS2-VASc and HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) were 4.9 and 3.0, respectively. At baseline, 85.4% of patients were taking anticoagulants and 71.3% patients were on antiplatelet therapy. The cohorts were well-balanced for baseline characteristics. The incremental LAAO procedure time was 38 minutes, and the median contrast volume used for combined procedures was 119 mL versus 70 mL with TAVR alone. At the 24-month follow-up, 82.5% compared with 50.8% of patients were on any antiplatelet therapy, and 13.9% compared with 66.7% of patients were on any anticoagulation therapy in TAVR + LAAO compared with TAVR + medical therapy group, respectively. For the composite primary end point, TAVR + LAAO was noninferior to TAVR + medical therapy (22.7 versus 27.3 events per 100 patient-years for TAVR + LAAO and TAVR + medical therapy, respectively; hazard ratio, 0.86 [95% CI, 0.60-1.22]; Pnoninferiority<0.001). CONCLUSIONS: Concomitant WATCHMAN LAAO and TAVR is noninferior to TAVR with medical therapy in severe aortic stenosis patients with AF. The increased complexity and risks of the combined procedure should be considered when concomitant LAAO is viewed as an alternative to medical therapy for patients with AF undergoing TAVR. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03173534.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kapadia, Krishnaswamy, Whisenant, et al. Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation. Circulation. 2023. PMID: 37874908. doi:10.1161/CIRCULATIONAHA.123.067312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。